title: Prevalence of primary HIV-1 drug resistance among recently infected adolescents: a multicenter adolescent medicine trials network for HIV/AIDS interventions study.
abstract: This study examined the prevalence of primary human immunodeficiency type 1 (HIV-1) drug resistance among recently infected youth in the United States. Of the 55 subjects studied, major mutations conferring HIV drug resistance were present in 10 (18%). Eight (15%) had nonnucleoside reverse-transcriptase inhibitor (NNRTI) mutations, with the majority (6) having the K103N mutation; 2 (4%) had nucleoside reverse-transcriptase inhibitor (NRTI) mutations; and 2 (4%) had protease inhibitor (PI) mutations. Phenotypic drug resistance was present in 12 (22%) subjects: 10 (18%) for NNRTIs, 2 (4%) for NRTIs, and 3 (5.5%) for PIs. The prevalence of primary HIV-1 drug resistance, particularly to NNRTIs, in this group of recently infected youth was high.
authors.affiliation: University of California, San Diego School of Medicine, San Diego, La Jolla, CA 92093-0672, USA. rviani@ucsd.edu
authors.forename: Rolando M
authors.initials: RM
authors.lastname: Viani
authors.forename: Ligia
authors.initials: L
authors.lastname: Peralta
authors.forename: Grace
authors.initials: G
authors.lastname: Aldrovandi
authors.forename: Bill G
authors.initials: BG
authors.lastname: Kapogiannis
authors.forename: Rick
authors.initials: R
authors.lastname: Mitchell
authors.forename: Stephen A
authors.initials: SA
authors.lastname: Spector
authors.forename: Yolanda S
authors.initials: YS
authors.lastname: Lie
authors.forename: Jodi M
authors.initials: JM
authors.lastname: Weidler
authors.forename: Michael P
authors.initials: MP
authors.lastname: Bates
authors.forename: Nancy
authors.initials: N
authors.lastname: Liu
authors.forename: Craig M
authors.initials: CM
authors.lastname: Wilson
mesh_terms: D000293:Adolescent; D000328:Adult; D019943:Amino Acid Substitution / Q000235:genetics; D019380:Anti-HIV Agents / Q000494:pharmacology*; D002648:Child; D024882:Drug Resistance, Viral / Q000235:genetics*; D005260:Female; D015658:HIV Infections / Q000453:epidemiology / Q000821:virology*; D016333:HIV Protease / Q000235:genetics; D054303:HIV Reverse Transcriptase / Q000235:genetics; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics*; D006801:Humans; D008297:Male; D009154:Mutation
chemical_list: D019380:Anti-HIV Agents; D054303:HIV Reverse Transcriptase; D016333:HIV Protease